Fig. 2: PF-477736 selectively kills LIMD1−/− cells independent of Chk1 inhibition.
From: Targeted therapy for LIMD1-deficient non-small cell lung cancer subtypes
A Dose–response curve of SCH900776 in HeLa isogenic LIMD1−/− lines. Cells were treated for 4 days before measuring viability and calculating surviving fraction (n = 3). B Bar chart of SF50 values from panel (A) (n = 3, one-way ANOVA). C Surviving fraction of HeLa isogenic LIMD1−/− lines transfected with siRNA against CHEK1 at 50 nM and 20 nM for 72 h (n = 3, two-way ANOVA). ns p > 0.05. D Immunoblot of Chk1 and LIMD1 in HeLa isogenic LIMD1−/− lines transfected with siRNA against CHEK1 (20 nM, 72 h) (n = 3).
